Zhejiang Medicine (600216.SH) plans to invest 157 million yuan to establish a partnership enterprise.

Zhejiang Medicine (600216.SH) announced that on March 9, 2026, the company signed a "Xiamen Huaben Qihang Equity Investment Partnership Enterprise (Limited Partnership) Agreement" with general partner Xiamen Huaben Contemporary Entrepreneurship Investment Management Co., Ltd., and limited partners Cai Xiaoyang, Yu Fengjia, and Yu Zhangxing, jointly investing in Xiamen Huaben Qihang Equity Investment Partnership Enterprise (Limited Partnership). The total subscribed capital of the partnership enterprise is 320 million yuan, with the company as a limited partner subscribing with its own funds of 157 million yuan, accounting for 49.06% of the total subscribed capital of the partnership enterprise. Xiamen Huaben Contemporary Entrepreneurship Investment Management Co., Ltd. serves as the general partner, executive partner, and fund manager of the partnership enterprise. The fund investment mainly focuses on strategic emerging industries such as biopharmaceuticals, with the investment proportion in the above-mentioned industries not less than 60% of the fund size.